Immunostimulatory Properties of Phosphorothioate CpG DNA Containing Both 3'-5'- and 2'-5'-internucleotide Linkages

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2002 Mar 28

PMID 11917022

Citations 8

Authors

Dong Yu

Ekambar R Kandimalla

Qiuyan Zhao

Yanping Cong

Sudhir Agrawal

Affiliations

Soon will be listed here.

Abstract

Synthetic oligodeoxyribonucleotides containing CpG-dinucleotides (CpG DNA) in specific sequence contexts activate the vertebrate immune system. We have examined the effect of 3'-deoxy-2'-5'-ribonucleoside (3'-deoxynucleoside) incorporation into CpG DNA on the immunostimulatory activity. Incorporation of 3'-deoxynucleosides results in the formation of 2'-5'-internucleotide linkages in an otherwise 3'-5'-linked CpG DNA. In studies, both in vitro and in vivo, CpG DNA containing unnatural 3'-deoxynucleoside either within the CpG-dinucleotide or adjacent to the CpG-dinucleotide failed to induce immunostimulatory activity, suggesting that the modification was not recognized by the receptors. Incorporation of the same modification distal to the CpG-dinucleotide in the 5'-flanking sequence potentiated the immunostimulatory activity of the CpG DNA. The same modification when incorporated in the 3'-flanking sequence had an insignificant effect on immunostimulatory activity of CpG DNA. Interestingly, substitution of a 3'-deoxynucleoside in the 5'-flanking sequence distal to the CpG-dinucleotide resulted in increased IL-6 and IL-10 secretion with similar levels of IL-12 compared with parent CpG DNA. The incorporation of the same modification in the 3'-flanking sequence resulted in lower IL-6 and IL-10 secretion with similar levels of IL-12 compared with parent CpG DNA. These results suggest that site-specific incorporation of 3'-deoxynucleotides in CpG DNA modulates immunostimulatory properties.

Citing Articles

The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.

Agrawal S Biomedicines. 2021; 9(5).

PMID: 34063675 PMC: 8147625. DOI: 10.3390/biomedicines9050503.

Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses.

Putta M, Bhagat L, Wang D, Zhu F, Kandimalla E, Agrawal S ACS Med Chem Lett. 2014; 4(2):302-5.

PMID: 24900663 PMC: 4027476. DOI: 10.1021/ml300482z.

Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.

Putta M, Zhu F, Li Y, Bhagat L, Cong Y, Kandimalla E Nucleic Acids Res. 2006; 34(11):3231-8.

PMID: 16798912 PMC: 1904100. DOI: 10.1093/nar/gkl430.

Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.

Kandimalla E, Bhagat L, Li Y, Yu D, Wang D, Cong Y Proc Natl Acad Sci U S A. 2005; 102(19):6925-30.

PMID: 15860583 PMC: 1100782. DOI: 10.1073/pnas.0501729102.

Impact of site-specific nucleobase deletions on the arthritogenicity of DNA.

Bjersing J, Tarkowski A, Kandimalla E, Karlsson H, Agrawal S, Collins L Inflammation. 2004; 28(3):159-68.

PMID: 15527171 DOI: 10.1023/b:ifla.0000039562.30451.0a.

References

Fiedler M, Lu M, Siegel F, Whipple J, Roggendorf M . Immunization of woodchucks (Marmota monax) with hepatitis delta virus DNA vaccine. Vaccine. 2001; 19(32):4618-26. DOI: 10.1016/s0264-410x(01)00245-6. View

Bhan P, Bhan A, Hong M, Hartwell J, Saunders J, Hoke G . 2',5'-linked oligo-3'-deoxyribonucleoside phosphorothioate chimeras: thermal stability and antisense inhibition of gene expression. Nucleic Acids Res. 1997; 25(16):3310-7. PMC: 146881. DOI: 10.1093/nar/25.16.3310. View

Yu D, Kandimalla E, Zhao Q, Cong Y, Agrawal S . Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases. Bioorg Med Chem Lett. 2001; 11(17):2263-7. DOI: 10.1016/s0960-894x(01)00418-8. View

Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B, Hammerling G . NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol. 2001; 167(9):5247-53. DOI: 10.4049/jimmunol.167.9.5247. View

Kandimalla E, Shaw D, Agrawal S . Effects of phosphorothioate oligodeoxyribonucleotide and oligoribonucleotides on human complement and coagulation. Bioorg Med Chem Lett. 1999; 8(16):2103-8. DOI: 10.1016/s0960-894x(98)00368-0. View

Giannaris P, Damha M . Oligoribonucleotides containing 2',5'-phosphodiester linkages exhibit binding selectivity for 3',5'-RNA over 3',5'-ssDNA. Nucleic Acids Res. 1993; 21(20):4742-9. PMC: 331500. DOI: 10.1093/nar/21.20.4742. View

Takeshita F, Leifer C, Gursel I, Ishii K, Takeshita S, Gursel M . Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol. 2001; 167(7):3555-8. DOI: 10.4049/jimmunol.167.7.3555. View

Yu D, Kandimalla E, Zhao Q, Cong Y, Agrawal S . Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg Med Chem. 2001; 9(11):2803-8. DOI: 10.1016/s0968-0896(01)00142-0. View

Premraj B, Patel P, Kandimalla E, Agrawal S, Hosur R, Yathindra N . NMR structure of a 2',5' RNA favors A type duplex with compact C2'endo nucleotide repeat. Biochem Biophys Res Commun. 2001; 283(3):537-43. DOI: 10.1006/bbrc.2001.4828. View

10.

Lipford G, Sparwasser T . Hematopoietic remodeling triggered by CpG DNA. Curr Top Microbiol Immunol. 2000; 247:119-29. DOI: 10.1007/978-3-642-59672-8_8. View

11.

Davis H, Suparto I, Weeratna R, Jumintarto , Iskandriati D, Chamzah S . CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine. 2000; 18(18):1920-4. DOI: 10.1016/s0264-410x(99)00443-0. View

12.

Zhao Q, Temsamani J, Iadarola P, Jiang Z, Agrawal S . Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol. 1996; 51(2):173-82. DOI: 10.1016/0006-2952(95)02177-9. View

13.

Hartmann G, Weeratna R, Ballas Z, Payette P, Blackwell S, Suparto I . Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol. 2000; 164(3):1617-24. DOI: 10.4049/jimmunol.164.3.1617. View

14.

Zimmermann S, Egeter O, Hausmann S, Lipford G, Rocken M, Wagner H . CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol. 1998; 160(8):3627-30. View

15.

Zhao Q, Temsamani J, Zhou R, Agrawal S . Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997; 7(5):495-502. DOI: 10.1089/oli.1.1997.7.495. View

16.

Agrawal S, Kandimalla E . Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr Cancer Drug Targets. 2002; 1(3):197-209. DOI: 10.2174/1568009013334160. View

17.

Zhao Q, Yu D, Agrawal S . Site of chemical modifications in CpG containing phosphorothioate oligodeoxynucleotide modulates its immunostimulatory activity. Bioorg Med Chem Lett. 2000; 9(24):3453-8. DOI: 10.1016/s0960-894x(99)00635-6. View

18.

Ballas Z, Krieg A, Warren T, Rasmussen W, Davis H, Waldschmidt M . Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001; 167(9):4878-86. DOI: 10.4049/jimmunol.167.9.4878. View

19.

Lewis E, Agrawal S, Bishop J, Chadwick J, Cristensen N, Cuthill S . Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. Antiviral Res. 2001; 48(3):187-96. DOI: 10.1016/s0166-3542(00)00129-7. View

20.

Shirota H, Sano K, Kikuchi T, Tamura G, Shirato K . Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator. J Immunol. 2000; 164(11):5575-82. DOI: 10.4049/jimmunol.164.11.5575. View